Oberlin-based Synapse Biomedical recently secured U.S. Food and Drug Administration premarket approval for its diaphragm pacing system for use in patients with spinal cord injuries (SCI) who rely on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback